ClinicalTrials.gg

Program

INCB057643

Its studies are mostly in Primary Myelofibrosis · Neoplasm Metastasis · Lymphoma, led by Incyte.

Furthest: phase 2, since Mar 9, 20164 company-led studies, 1 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte41 open or runningphase 2since Mar 9, 2016Mar 9, 2016Apr 30, 2027phase 1 · NCT04279847

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2016First study: phase 2 study in LymphomaFirst studyNCT02711137 · 137 enrolled · United States, Belgium, France
  2. Nov 7, 2016Phase 2 study in Neoplasm MetastasisNCT02959437 · 70 enrolled · United States, Spain, United Kingdom
  3. Feb 18, 2020Phase 1 study in Primary MyelofibrosisNCT04279847 · 140 enrolled · United States, Canada, China and more
  4. Apr 16, 2025Phase 1 study in Healthy VolunteersNCT06941077 · 48 enrolled · United States

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Primary MyelofibrosisNCT04279847

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06941077Healthy Volunteers · United States1CompletedJun 3, 202548
NCT04279847Primary Myelofibrosis · United States, Canada, China and more1Active, not recruitingApr 30, 2027140
NCT02959437Neoplasm Metastasis · United States, Spain, United Kingdom2TerminatedFeb 15, 201970
NCT02711137Lymphoma · United States, Belgium, France2TerminatedFeb 13, 2019137

How it is read

Names in the registry

  • “INCB057643”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.